RU2315756C2 - Амиды антраниловой кислоты и их применение в фармацевтике - Google Patents

Амиды антраниловой кислоты и их применение в фармацевтике Download PDF

Info

Publication number
RU2315756C2
RU2315756C2 RU2004117548/04A RU2004117548A RU2315756C2 RU 2315756 C2 RU2315756 C2 RU 2315756C2 RU 2004117548/04 A RU2004117548/04 A RU 2004117548/04A RU 2004117548 A RU2004117548 A RU 2004117548A RU 2315756 C2 RU2315756 C2 RU 2315756C2
Authority
RU
Russia
Prior art keywords
formula
compound
denotes
acid amide
anthranilic acid
Prior art date
Application number
RU2004117548/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2004117548A (ru
Inventor
Гуидо Больд
Паскаль Фюре
Пол Уилльям МАНЛИ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2004117548A publication Critical patent/RU2004117548A/ru
Application granted granted Critical
Publication of RU2315756C2 publication Critical patent/RU2315756C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
RU2004117548/04A 2001-11-08 2002-11-07 Амиды антраниловой кислоты и их применение в фармацевтике RU2315756C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0126901.8A GB0126901D0 (en) 2001-11-08 2001-11-08 Organic compounds
GB0126901.8 2001-11-08
GBGB0212917.9A GB0212917D0 (en) 2001-11-08 2002-06-05 Organic compounds
GB0212917.9 2002-06-05

Publications (2)

Publication Number Publication Date
RU2004117548A RU2004117548A (ru) 2005-06-10
RU2315756C2 true RU2315756C2 (ru) 2008-01-27

Family

ID=26246753

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004117548/04A RU2315756C2 (ru) 2001-11-08 2002-11-07 Амиды антраниловой кислоты и их применение в фармацевтике

Country Status (25)

Country Link
US (1) US7067543B2 (enExample)
EP (2) EP2269988B1 (enExample)
JP (1) JP4179989B2 (enExample)
KR (1) KR100633814B1 (enExample)
CN (1) CN100467450C (enExample)
AR (1) AR037261A1 (enExample)
AT (1) ATE494278T1 (enExample)
AU (1) AU2002342889B2 (enExample)
BR (1) BR0213939A (enExample)
CA (1) CA2462390C (enExample)
DE (1) DE60238856D1 (enExample)
GB (2) GB0126901D0 (enExample)
HR (1) HRP20040412A2 (enExample)
IL (1) IL161163A0 (enExample)
MX (1) MXPA04004390A (enExample)
MY (1) MY136322A (enExample)
NO (1) NO326986B1 (enExample)
NZ (1) NZ532587A (enExample)
PE (1) PE20030540A1 (enExample)
PL (1) PL368417A1 (enExample)
PT (1) PT1446381E (enExample)
RS (1) RS29404A (enExample)
RU (1) RU2315756C2 (enExample)
TW (1) TWI260985B (enExample)
WO (1) WO2003040101A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
ES2619203T3 (es) 2004-01-28 2017-06-23 Mitsui Chemicals Agro, Inc. Derivados de amida, procesos para la producción de los mismos y método para su aplicación como insecticidas
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
WO2006070878A1 (ja) * 2004-12-28 2006-07-06 Astellas Pharma Inc. カルボン酸誘導体またはその塩
EP2145873A1 (fr) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Nouveaux composés ayant une activité protectrice vis-à-vis de l'action de toxines et de virus au mode d'action intracellulaire
AR073216A1 (es) 2008-08-27 2010-10-20 Leo Pharma As Derivados de piridina como receptor de vegfr-2 e inhibidores de proteina tirosina quinasa y uso farmaceutico de los mismos
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226394A (en) * 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
RU2128644C1 (ru) * 1993-12-27 1999-04-10 Эйсай Ко., Лтд. Производные антраниловой кислоты или их фармакологически приемлемые соли, промежуточные продукты для их получения и лекарственный препарат на их основе
WO2000027820A1 (en) * 1998-11-10 2000-05-18 Novartis Ag N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
WO1998014449A1 (en) 1996-10-02 1998-04-09 Novartis Ag Fused pyrazole derivatives and processes for their preparation
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226394A (en) * 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
RU2128644C1 (ru) * 1993-12-27 1999-04-10 Эйсай Ко., Лтд. Производные антраниловой кислоты или их фармакологически приемлемые соли, промежуточные продукты для их получения и лекарственный препарат на их основе
WO2000027820A1 (en) * 1998-11-10 2000-05-18 Novartis Ag N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors

Also Published As

Publication number Publication date
RS29404A (sr) 2007-02-05
NO20042137L (no) 2004-05-25
EP2269988A2 (en) 2011-01-05
HRP20040412A2 (en) 2005-06-30
DE60238856D1 (de) 2011-02-17
MY136322A (en) 2008-09-30
IL161163A0 (en) 2004-08-31
EP1446381A1 (en) 2004-08-18
TWI260985B (en) 2006-09-01
KR100633814B1 (ko) 2006-10-13
JP2005508382A (ja) 2005-03-31
PT1446381E (pt) 2011-01-31
KR20050044374A (ko) 2005-05-12
TW200300086A (en) 2003-05-16
AR037261A1 (es) 2004-11-03
GB0212917D0 (en) 2002-07-17
NO326986B1 (no) 2009-03-30
EP1446381B1 (en) 2011-01-05
CA2462390C (en) 2011-01-11
PE20030540A1 (es) 2003-08-05
CA2462390A1 (en) 2003-05-15
EP2269988B1 (en) 2012-05-23
US20040248947A1 (en) 2004-12-09
JP4179989B2 (ja) 2008-11-12
MXPA04004390A (es) 2005-05-16
RU2004117548A (ru) 2005-06-10
ATE494278T1 (de) 2011-01-15
US7067543B2 (en) 2006-06-27
EP2269988A3 (en) 2011-02-16
WO2003040101A1 (en) 2003-05-15
PL368417A1 (en) 2005-03-21
NZ532587A (en) 2006-02-24
CN100467450C (zh) 2009-03-11
GB0126901D0 (en) 2002-01-02
CN1578768A (zh) 2005-02-09
AU2002342889B2 (en) 2007-03-01
BR0213939A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
KR100602977B1 (ko) 안트라닐산 아미드 및 ｖｅｇｆ 수용체 티로신 키나제억제제로서 그의 용도
AU2002351909A1 (en) Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors
KR100633814B1 (ko) 안트라닐산 아미드 및 그의 제약상 용도
EP1572686B1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
ES2359395T3 (es) Amidas de acido antranílico y su uso farmacéutico.
NZ543915A (en) Anthranilic acid amides for use in retinopathy or neoplastic disease, and their process of preparation
ZA200402623B (en) Anthranillic acid amides and pharmaceutical use thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20111108